Boston Scientific has agreed to acquire Penumbra for $14.5 billion, marking one of the largest medical device deals of the year. The acquisition strengthens Boston Scientific’s cardiovascular portfolio and pushes Penumbra stock to record highs. The deal could reshape treatment options for stroke and pulmonary embolism patients.
Marlborough, United States | 15 January 2026



